Theravance Biopharma, Inc. reported significant financial improvements in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated total revenues of $26.2 million for the quarter, an increase of 84% compared to $14.3 million in the same period last year. For the first half of 2025, revenues reached $41.6 million, up 45% from $28.8 million in the first half of 2024. This growth was primarily driven by a $7.5 million licensing revenue milestone from the regulatory approval of YUPELRI in China and a 31% increase in revenue from the Viatris collaboration agreement, which totaled $18.7 million for the quarter.
The company also reported a net income of $54.8 million for the second quarter of 2025, a substantial turnaround from a net loss of $16.5 million in the same quarter of the previous year. This positive shift was largely attributed to a net gain of $75.1 million from the sale of future royalty rights related to the TRELEGY product to GSK, which was finalized in June 2025. The net income per share for the quarter was $1.09, compared to a loss of $0.34 per share in the prior year.
In terms of operational developments, Theravance Biopharma's cash and cash equivalents surged to $281.9 million as of June 30, 2025, up from $37.8 million at the end of 2024. This increase was primarily due to the aforementioned sale of TRELEGY royalties and a $50 million milestone payment from Royalty Pharma. The company’s total assets also rose to $426 million, reflecting a strong liquidity position that is expected to support operations for at least the next twelve months.
The company has made strategic advancements in its product pipeline, particularly with YUPELRI, which received regulatory approval in China in June 2025. This approval not only triggered a milestone payment but also positions the company for potential future revenue growth in the Chinese market. Additionally, the company is advancing its investigational drug ampreloxetine, which is in Phase 3 trials for treating neurogenic orthostatic hypotension in patients with multiple system atrophy.
Looking ahead, Theravance Biopharma remains optimistic about its growth trajectory, bolstered by its strong cash position and ongoing product development efforts. The company anticipates continued revenue generation from YUPELRI and potential milestone payments from Royalty Pharma, which could further enhance its financial stability and operational capacity in the coming quarters.
About Theravance Biopharma, Inc.
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines for respiratory and neurological conditions. Its key products include YUPELRI for COPD and investigational therapies like ampreloxetine for neurogenic orthostatic hypotension in MSA patients. The company leverages strategic partnerships, patent protections, and a diversified development pipeline to deliver innovative treatments and create shareholder value.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.